Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.
- Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.
- Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the companys portfolio of innovative assets.
- Todays exciting announcement helps us to build on our strong nephrology pipeline to help end-stage kidney disease patients globally, commented Abbas Hussain, Chief Executive Officer of Vifor Pharma Group.
- We are excited to join forces with Vifor Pharma, which has a world-renowned commitment to patient focused cardio-renal therapies.